Effectiveness and safety of pemetrexed for non-small cell lung cancer in the Andalusian Public Health System
Objective: To evaluate effectiveness and safety profile of pemetrexed in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) when it´s used on real clinical practice in Andalusia (a Spanish region with 8.5 million inhabitants, 2014 census data). Methods: An observational...
Saved in:
| Main Authors: | María Antonia Pérez-Moreno, Jesús Cotrina-Luque, Mercedes Galván-Banqueri, Sandra Flores-Moreno, Francisco Javier Bautista-Paloma, Miguel Ángel Calleja-Hernández |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2016-11-01
|
| Series: | Farmacia Hospitalaria |
| Subjects: | |
| Online Access: | http://www.aulamedica.es/fh/pdf/10424.pdf |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Cytotoxic mechanisms of pemetrexed and HDAC inhibition in non-small cell lung cancer cells involving ribonucleotides in DNA
by: Tobias Solli Iveland, et al.
Published: (2025-01-01) -
Cost-effectiveness of pemetrexed in combination with cisplatin as first line treatment for patients with advanced non-squamous non-small-cell
by: Jonathan González García, et al.
Published: (2017-01-01) -
Pembrolizumab plus Pemetrexed and Platinum in Metastatic Non-Squamous Non-Small Cell Lung Cancer: A Real-Life Study at a Portuguese Centre
by: Maria João Santos, et al.
Published: (2025-02-01) -
Pembrolizumab and Pemetrexed for Older Patients With Nonsquamous NSCLC and Programmed Cell Death-Ligand 1 Tumor Proportion Scores of Less Than 50%
by: Yoshihito Kogure, MD, PhD, et al.
Published: (2025-03-01) -
Patients outcomes in lung adenocarcinoma transforming to small-cell lung cancer after tyrosine kinase inhibitor therapy
by: Shuai Wang, et al.
Published: (2025-02-01)